Table 1.
Participant demographic data. Statistical difference from non-infected (control) group indicated by * (p < 0.05).
| Non-Infected (n = 8) | Infected (n = 8) | p-value | |
|---|---|---|---|
| Female (N(%)) | 3 (37.5) | 3 (37.5) | >0.999 |
| Age (yrs) | 32.6 ± 7.1 | 34.6 ± 7.6 | 0.597 |
| Height (cm) | 172.9 ± 11.9 | 173.0 ± 9.0 | 0.993 |
| Weight (kg) | 68.3 ± 10.1 | 70.6 ± 14.2 | 0.711 |
| Resting HR (bpm) | 70.5 ± 7.7 | 73.5 ± 12.5 | 0.573 |
| Resting Systolic Blood Pressure (mmHg) | 114.4 ± 6.6 | 115 ± 11.0 | 0.892 |
| Resting Diastolic Blood Pressure (mmHg) | 75.3 ± 5.8 | 77.1 ± 7.3 | 0.579 |
| PAR Score (1–7) | 5.9 ± 0.8 | 5.5 ± 1.8 | 0.597 |
| Predicted VO2max (mL/kg/min) | 44.9 ± 7.14 | 33.6 ± 11.2 * | 0.033 |
| Peak Power (watts) | 214.4 ± 43.0 | 187.5 ± 56.6 | 0.302 |
| Spike IgG (ug/mL) | 0.4 ± 0.31 | 6.24 ± 3 * | <0.001 |
| CMV Serostatus (N (%)) | 4 (50) | 3 (37.5) | >0.999 |
| EBV Serostatus (N (%)) | 7 (87.5) | 8 (100) | >0.999 |